Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tropifexor in primary biliary cholangitis
2015-001590-41Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Tropifexor with Placebo (2 arms). Primary endpoints: Change in cholestatic markers from baseline and Safety and tolerability of daily tropifexor. Started Jan 2016; status: terminated.
02
Drugs
tropifexor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2015-001590-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001590-41.